Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) have been assigned a consensus recommendation of “Hold” from the eight analysts that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating on the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $22.20.

OCUL has been the topic of several research reports. Zacks Investment Research downgraded Ocular Therapeutix from a “hold” rating to a “sell” rating in a report on Wednesday, October 25th. ValuEngine downgraded Ocular Therapeutix from a “sell” rating to a “strong sell” rating in a report on Thursday, September 21st. HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Ocular Therapeutix in a report on Wednesday, November 8th. Cantor Fitzgerald reiterated a “buy” rating and issued a $21.00 price target on shares of Ocular Therapeutix in a report on Monday, September 25th. Finally, Guggenheim started coverage on Ocular Therapeutix in a report on Monday, October 23rd. They issued a “buy” rating and a $12.00 price target on the stock.

In other Ocular Therapeutix news, insider Daniel M. Bollag acquired 24,700 shares of the stock in a transaction dated Wednesday, December 6th. The stock was purchased at an average price of $3.93 per share, with a total value of $97,071.00. Following the transaction, the insider now directly owns 24,700 shares of the company’s stock, valued at $97,071. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Chairman Amarpreet Sawhney acquired 19,000 shares of the stock in a transaction dated Thursday, November 16th. The stock was acquired at an average cost of $5.18 per share, with a total value of $98,420.00. Following the transaction, the chairman now directly owns 696,390 shares in the company, valued at $3,607,300.20. The disclosure for this purchase can be found here. Insiders bought a total of 48,500 shares of company stock worth $214,691 over the last quarter. Company insiders own 26.10% of the company’s stock.

Several institutional investors have recently bought and sold shares of the company. TIAA CREF Investment Management LLC boosted its position in shares of Ocular Therapeutix by 0.7% in the 2nd quarter. TIAA CREF Investment Management LLC now owns 111,019 shares of the biopharmaceutical company’s stock worth $1,029,000 after purchasing an additional 785 shares in the last quarter. Nationwide Fund Advisors boosted its position in shares of Ocular Therapeutix by 10.8% in the 2nd quarter. Nationwide Fund Advisors now owns 12,344 shares of the biopharmaceutical company’s stock worth $114,000 after purchasing an additional 1,204 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in shares of Ocular Therapeutix by 4.4% in the 2nd quarter. Goldman Sachs Group Inc. now owns 33,417 shares of the biopharmaceutical company’s stock worth $310,000 after purchasing an additional 1,422 shares in the last quarter. Alps Advisors Inc. boosted its position in shares of Ocular Therapeutix by 5.9% in the 2nd quarter. Alps Advisors Inc. now owns 26,201 shares of the biopharmaceutical company’s stock worth $243,000 after purchasing an additional 1,462 shares in the last quarter. Finally, Teachers Advisors LLC lifted its position in Ocular Therapeutix by 6.2% during the 2nd quarter. Teachers Advisors LLC now owns 42,679 shares of the biopharmaceutical company’s stock worth $396,000 after acquiring an additional 2,500 shares during the period. 52.94% of the stock is owned by hedge funds and other institutional investors.

Ocular Therapeutix (NASDAQ:OCUL) opened at $4.15 on Monday. Ocular Therapeutix has a fifty-two week low of $3.30 and a fifty-two week high of $11.79. The company has a quick ratio of 4.78, a current ratio of 4.79 and a debt-to-equity ratio of 0.39.

Ocular Therapeutix (NASDAQ:OCUL) last released its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.54) EPS for the quarter, hitting the consensus estimate of ($0.54). The company had revenue of $523.00 million for the quarter, compared to the consensus estimate of $0.52 million. Ocular Therapeutix had a negative return on equity of 126.31% and a negative net margin of 3,241.19%. Ocular Therapeutix’s quarterly revenue was up 9.6% on a year-over-year basis. During the same period last year, the business posted ($0.39) EPS. equities analysts predict that Ocular Therapeutix will post -2.37 earnings per share for the current year.

WARNING: “Ocular Therapeutix, Inc. (OCUL) Given Consensus Rating of “Hold” by Brokerages” was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/12/11/ocular-therapeutix-inc-ocul-given-consensus-rating-of-hold-by-brokerages.html.

About Ocular Therapeutix

Ocular Therapeutix, Inc is a biopharmaceutical company focused on the development, manufacturing and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its lead product candidate, DEXTENZA (dexamethasone insert) for intracanalicular use, has completed Phase III clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery.

Analyst Recommendations for Ocular Therapeutix (NASDAQ:OCUL)

Receive News & Ratings for Ocular Therapeutix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.